Methods of treating chronic spontaneous urticaria using ligelizumab
AssigneeNovartis AG
InventorsReinhold Martin JANOCHA, Stephan KOEHNE-VOSS, Philip John LOWE, Thomas SEVERIN
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for treating Chronic Spontaneous Urticaria using IgE antagonists, e.g., ligelizumab. Also disclosed herein are IgE antagonists, e.g., IgE antibodies, such as ligelizumab, for treating Chronic Spontaneous Urticaria patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.
Claims30
A method of treating chronic spontaneous urticaria (CSU), comprising subcutaneously (SC) administering to a patient in need thereof a dose of about 24 mg—about 240 mg of an anti-IgE antibody, or an antigen binding fragment thereof, during week 0, and thereafter SC at a dose of about 24 mg-about 240 mg monthly (every 4 weeks), beginning during week 4;
- wherein the anti-IgE antibody or antigen binding fragment thereof comprises:
- a variable light chain region (VL) comprising CDRL1, CDRL2, and CDRL3 and a variable heavy chain region (VH) comprising CDRH1, CDRH2, and CDRH3, wherein CDRL1 consists of SEQ ID NO:3, CDRL2 consists of SEQ ID NO:4, CDRL3 consists of SEQ ID NO:5, CDRH1 consists of SEQ ID NO:6, CDRH2 consists of SEQ ID NO:7, and CDRH3consists of SEQ ID NO:8.
-32. (canceled)
Dependencies are inferred from the claim text.